Last reviewed · How we verify
adjuvanted trivalent influenza vaccine
An adjuvanted trivalent influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus.
An adjuvanted trivalent influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | adjuvanted trivalent influenza vaccine |
|---|---|
| Also known as | Fluad, aTIV |
| Sponsor | Insight Therapeutics, LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated antigens from three influenza virus strains (typically two A subtypes and one B lineage) combined with an adjuvant that enhances the immune response. The adjuvant amplifies both humoral (antibody) and cell-mediated immunity, improving vaccine efficacy and duration of protection compared to non-adjuvanted formulations. This approach is particularly beneficial in populations with weaker immune responses, such as elderly individuals.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults (PHASE2)
- Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) (PHASE3)
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 (PHASE2)
- CT18 Infant Influenza Priming Study in Vaccine Naive Infants (PHASE2)
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: